Ascendis Pharma director reports warrant holdings

Ascendis Pharma A/S director Jean Jacques Bienaimé filed an initial ownership report showing a warrant position rather than common shares.

Rhea-AI Filing Summary

Ascendis Pharma A/S director Jean Jacques Bienaimé filed an initial ownership report showing a warrant position rather than common shares. He directly holds warrants exercisable for 9,160 Ordinary Shares, with an exercise price of $172.35 per share and expiration on June 10, 2035. The warrants vest 25% on June 10, 2026 and then in 36 equal monthly installments. The filing also indicates he holds no Ordinary Shares directly as of the reporting date, and notes that the position includes American Depositary Shares, with each ADS representing one Ordinary Share.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BIENAIME JEAN JACQUES

Role Director

Type	Security	Shares	Price	Value
holding	Warrants	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Warrants — 9,160 contracts (Direct); Ordinary Shares — 0 shares (Direct)

Footnotes (2)

1. F1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
2. F2. The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.

Key Figures

Underlying warrant shares: 9,160 shares Warrant exercise price: $172.35 per share Warrant expiration date: June 10, 2035 +3 more

6 metrics

Underlying warrant shares 9,160 shares Ordinary Shares underlying warrants, direct holding

Warrant exercise price $172.35 per share Exercise price for Ordinary Shares under warrants

Warrant expiration date June 10, 2035 Expiration date of warrants over Ordinary Shares

Initial vesting date June 10, 2026 25% of warrants vest on this date

Remaining vesting schedule 36 monthly installments Post-initial vesting pattern for remaining warrants

Ordinary Shares held 0 shares Total Ordinary Shares directly owned after reporting

Key Terms

American Depositary Shares ("ADS"), Warrants, Ordinary Shares, vesting

4 terms

American Depositary Shares ("ADS") financial

"Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share."

American depositary shares are U.S.-listed certificates issued by a bank that represent ownership in shares of a foreign company, trading on American exchanges in dollars. Think of them as voucher tickets that let U.S. investors buy and sell foreign stock without handling foreign exchanges, currencies, or settlement rules directly. They matter because they make cross-border investing simpler and can affect liquidity, dividend payments and currency exposure for investors.

Warrants financial

"The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments."

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Ordinary Shares financial

"underlying_security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vesting financial

"The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Ascendis Pharma (ASND) director Jean Jacques Bienaimé report on Form 3?

Jean Jacques Bienaimé reported holding warrants over 9,160 Ordinary Shares of Ascendis Pharma A/S. These warrants represent his initial disclosed beneficial ownership and include equivalent American Depositary Shares (ADS), with each ADS corresponding to one Ordinary Share of the company.

What is the exercise price of the warrants reported by Ascendis Pharma (ASND) director Bienaimé?

The warrants held by Jean Jacques Bienaimé are exercisable at $172.35 per Ordinary Share. This exercise price defines the cost per share if the warrants are exercised and is a key term governing the economic value of his derivative position in Ascendis Pharma A/S.

When do Jean Jacques Bienaimé’s Ascendis Pharma (ASND) warrants vest and expire?

Bienaimé’s warrants vest 25% on June 10, 2026, with the remaining portion vesting in 36 equal monthly installments. The warrants carry an expiration date of June 10, 2035, establishing a long-dated timeframe during which he may choose to exercise this derivative position.

Does Ascendis Pharma (ASND) director Bienaimé directly own any Ordinary Shares in this Form 3 filing?

The filing shows Bienaimé directly owning 0 Ordinary Shares following the reported positions. His disclosed economic exposure comes entirely through warrants over 9,160 underlying Ordinary Shares, rather than through currently held common equity in Ascendis Pharma A/S.

How are Ascendis Pharma (ASND) American Depositary Shares (ADS) treated in Bienaimé’s Form 3?

The footnotes explain that the reported position includes American Depositary Shares (ADS). Each ADS represents one Ordinary Share, so the 9,160 underlying Ordinary Shares covered by the warrants correspond to the same number of ADS, aligning the derivative exposure across both share formats.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP

(City) (State) (Zip)

DENMARK

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(2)	06/10/2035	Ordinary Shares	9,160	$172.35	D

Explanation of Responses:

1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

2. The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.

	/s/ Michael Wolff Jensen as attorney-infact for Jean J Bienaime	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)